Skip to main content

Peer Review reports

From: RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial

Original Submission
27 Jul 2018 Submitted Original manuscript
21 Aug 2018 Reviewed Reviewer Report - Susan Dutton
17 Sep 2018 Author responded Author comments - Sean Lim
Resubmission - Version 2
17 Sep 2018 Submitted Manuscript version 2
16 Oct 2018 Editorially accepted
9 Nov 2018 Article published 10.1186/s13063-018-2996-6

You can find further information about peer review here.

Back to article page